Skip to content
naulon

Not checkedNot checked for notices yet.

Treatment Progress for EGFR Wild-type Advanced Non-small Cell Lung Cancer

Feng MA, Xiaoyu SHI, Wei MENG and 4 more

Chinese Journal of Lung Cancer · 2014

doi:10.3779/j.issn.1009-3419.2014.07.14 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Lung cancer is the leading cause of death from cancer in the world. The treatment remains one of the most challenging tasks in the medical world. The discovery and development of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) have had a major impact in the treatment of non small cell lung cancer (NSCLC). But the efficacy of EGFR-TKI in EGFR wild-type patients is limited, and the limited EGFR mutation incidence also prompts researchers to study what is the best treatment choice for patients with NSCLC who are negative for EGFR mutations. This review will discuss the research status in treatment choice for EGFR wild-type NSCLC.

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.